ClinicalTrials.gg

Program

givinostat

Also written as “Givinostat”, “ITF2357” and “ITF2357 10 mg/mL”.

Its studies are mostly in Muscular Dystrophy, Duchenne · Polycythemia Vera · Arthritis, Juvenile · Hodgkin Disease · Myeloproliferative Disorders, led by Italfarmaco.

Furthest: phase 3, since Jul 27, 201623 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Italfarmaco234 open or runningphase 3since Jul 27, 2016Jul 3, 2007Dec 2026phase 2 · NCT01761968

Also a collaborator on its studies: fortrea, biotrial, ppd-development-lp, cromsource and parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Jul 3, 2007.

  1. Jun 25, 2009Phase 2 study in Polycythemia VeraNCT00928707 · 45 enrolled · Italy
  2. Dec 15, 2010Phase 2 study in Arthritis, JuvenileNCT01261624 · 16 enrolled · Belgium, Czech Republic, Italy and more
  3. Mar 14, 2012No phase study in Arthritis, JuvenileNCT01557452 · 1 enrolled · Czechia
  4. Dec 18, 20122 phase 2 studiesNCT01761968, NCT01761292
  5. Jul 10, 2013Phase 2 study in Polycythemia VeraNCT01901432 · 48 enrolled · France, Germany, Italy and more
  6. Jul 27, 2016Phase 3 study in Muscular Dystrophy, DuchenneNCT02851797 · 179 enrolled · United States, Belgium, Canada and more
  7. Jul 12, 2017Phase 2 study in Muscular Dystrophy, DuchenneNCT03238235 · 51 enrolled · Italy, Netherlands
  8. Dec 4, 2017Phase 3 study in Muscular Dystrophy, DuchenneNCT03373968 · 206 planned · United States, Belgium, Canada and more
  9. Mar 26, 2021Phase 1 study in Muscular Dystrophy, DuchenneNCT04821063 · 31 enrolled · Canada
  10. Jun 9, 2022Phase 1 study in Drug-Drug InteractionNCT05492318 · 26 enrolled · Portugal
  11. Apr 26, 20232 phase 1 studies in Drug Drug InteractionNCT05860114, NCT05845567
  12. Jun 16, 2023Phase 3 study in Muscular Dystrophy, DuchenneNCT05933057 · 138 planned · Belgium, Canada, Czechia and more
  13. Oct 10, 2023Phase 3 study in Polycythemia VeraNCT06093672 · 220 planned · United States, Austria, Bulgaria and more
  14. Dec 6, 2024Phase 1 study in Hepatic ImpairmentNCT06736223 · 24 enrolled · Bulgaria, France

Ahead

  1. Dec 2026Primary completion: phase 2 study in Myeloproliferative DisordersNCT01761968
  2. Feb 2028Primary completion: phase 3 study in Muscular Dystrophy, DuchenneNCT05933057
  3. Dec 2029Primary completion: phase 3 study in Muscular Dystrophy, DuchenneNCT03373968

TargetBeta

“Histone deacetylase inhibitor”ChEMBL 37, by rule

Other programs on the same 11 targets

ProgramCompanyFurthest phaseStudies
givinostat hydrochlorideruleItalfarmacophase 21

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06736223Hepatic Impairment · Bulgaria, France1CompletedAug 14, 202524
NCT06093672Polycythemia Vera · United States, Austria, Bulgaria and more3RecruitingJul 2026220
NCT05933057Muscular Dystrophy, Duchenne · Belgium, Canada, Czechia and more3RecruitingFeb 2028138
NCT05860114Drug Drug Interaction · Portugal1CompletedMay 8, 20228
NCT05845567Drug Drug Interaction · Portugal1CompletedMay 8, 202220
NCT05492318Drug-Drug Interaction · Portugal1CompletedMay 8, 202226
NCT04821063Muscular Dystrophy, Duchenne · Canada1CompletedJun 18, 202131
NCT03373968Muscular Dystrophy, Duchenne · United States, Belgium, Canada and more3RecruitingDec 2029206
NCT03238235Muscular Dystrophy, Duchenne · Italy, Netherlands2CompletedMar 19, 202151
NCT02851797Muscular Dystrophy, Duchenne · United States, Belgium, Canada and more3CompletedFeb 22, 2022179
NCT01901432Polycythemia Vera · France, Germany, Italy and more2CompletedJun 26, 201748
NCT01761292Muscular Dystrophy, Duchenne · Italy2CompletedDec 201420
NCT01761968Myeloproliferative Disorders · Germany, Italy, United Kingdom2Active, not recruitingDec 202690
NCT01557452Arthritis, Juvenile · Czechia–TerminatedJan 27, 20141
NCT01261624Arthritis, Juvenile · Belgium, Czech Republic, Italy and more2TerminatedJun 201216
NCT00928707Polycythemia Vera · Italy2CompletedJul 201145
NCT00792467Hodgkin Disease · Italy2CompletedJul 201024
NCT00792831Leukemia, Lymphocytic, Chronic, B-Cell · Italy2TerminatedApr 20093
NCT00792740Crohn Disease · Belgium, Italy, Netherlands2TerminatedDec 200851
NCT00792506Multiple Myeloma · Italy2TerminatedJan 20101
NCT00606307Polycythemia Vera · Italy2CompletedDec 200829
NCT00570661Active Systemic · Romania, Serbia2CompletedAug 25, 200817
NCT00496431Hodgkin Disease · Italy2TerminatedMar 200919

How it is read

Names in the registry

  • “Givinostat”, 10 entries
  • “ITF2357”, 7 entries
  • “givinostat”, 2 entries
  • “ITF2357 10 mg/mL”, 2 entries
  • “Givinostat 10 mg/mL”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.